Carcinoid syndrome & neuroendocrine tumours
Endocrine · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Neuroendocrine tumours are slow-growing neoplasms (commonly gut/pancreas or lung) that may secrete bioactive amines/peptides. Carcinoid syndrome — flushing, diarrhoea and bronchospasm — occurs mainly once hepatic metastases allow serotonin to reach the systemic circulation. Diagnose biochemically and on specialised imaging, and watch for carcinoid crisis.
Red flags
- Refer to a neuroendocrine tumour multidisciplinary team/endocrinology for all confirmed or suspected NETs
- Admit and give intravenous octreotide for carcinoid crisis, and refer carcinoid heart disease to cardiology for valve assessment
Assessment
Investigations
- 24-hour urinary 5-HIAA and plasma chromogranin A; gut-hormone profile for pancreatic NETs
- Localise with CT/MRI plus somatostatin-receptor imaging (Ga-68 DOTATATE PET)
- Echocardiography for carcinoid heart disease; histology grades the tumour
Management
- Somatostatin analogues (octreotide/lanreotide) control symptoms and slow growth; surgical resection/debulking where feasible, and liver-directed therapy for metastases
- Options include peptide-receptor radionuclide therapy (PRRT), everolimus/sunitinib and telotristat for refractory diarrhoea
- Cover procedures with octreotide to prevent carcinoid crisis
Disposition
Refer to a neuroendocrine tumour multidisciplinary team/endocrinology for all confirmed or suspected NETs.
Complications & pitfalls
- Carcinoid crisis (profound flushing, bronchospasm and haemodynamic collapse, often peri- procedure), carcinoid heart disease with right heart failure, bowel obstruction/mesenteric fibrosis, and niacin-deficiency pellagra from serotonin diversion
Exam pearls
- Carcinoid syndrome usually means liver metastases — gut serotonin is otherwise cleared first-pass by the liver. Always give octreotide cover before operating on or manipulating a NET, because tumour handling can precipitate a life-threatening carcinoid crisis.
- Monitoring & follow-up: Serial chromogranin A/5-HIAA and cross-sectional/receptor imaging for progression; periodic echocardiography. Specialist NET multidisciplinary follow-up; ensure octreotide cover is documented before any surgery or anaesthesia.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.